[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$faNOWEIC5fUHi_ZQBENBnUpBSZkgKDecyR2uccOb7LRg":8,"$fJqAPXBa7SOQFm-3xUTVIKZEJegJc16lh9Ss8jSoir0k":61,"$fpq6WOdofMSVV7r9owqKxHGVL4S6QQrzkjoktp-X6wPM":62,"$fdhsTBLwTjK7cmFKV3VNh41K1a9HFvujySTCpYuxsM44":65},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":60},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":22,"videoTotal":23,"isConcern":7,"title":24,"coverVertical":25,"coverAcross":26,"directionMarker":27,"description":28,"vid":29,"time":30,"mediaType":27,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":33,"seoKeywords":34,"seoDescription":35,"shelvesTime":36,"menus":37,"menuId":39,"type":56,"quality":57,"commentCount":17,"isComment":27,"deviceType":58,"url":59},10197,869990,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//ATJTmMPg3AzLFf5VSERBZjl8TZBHpsHb.png","刘振威",0,"慢性气道疾病、呼吸相关疾病","上海市第一人民医院","呼吸内科","主任医师",5,10,"新型药物提升哮喘的控制率","","https://cdn.yishi-tong.com/console/3/VTtoQNX9DJO91XQwpLrtMOXemj-Y8wa5.png",1,"WEBVTT\n\n00:00.755 --> 00:01.404\n你好。\n\n00:02.246 --> 00:05.946\n今天我和大家讨论的是新型药物提升。\n\n00:06.811 --> 00:08.112\n哮喘的控制率。\n\n00:17.732 --> 00:19.132\n首先第一个内容，\n\n00:19.132 --> 00:20.783\n药物研发的背景。\n\n00:23.215 --> 00:24.615\n哮喘的治疗现状。\n\n00:26.992 --> 00:29.041\n药材药物的种类。\n\n00:30.163 --> 00:32.513\n目前那个哮喘药物。\n\n00:33.297 --> 00:35.047\n药物的种类吧，\n\n00:35.097 --> 00:35.797\n它是。\n\n00:37.660 --> 00:38.311\n都要处分。\n\n00:39.687 --> 00:42.088\n目前是这几个方面，\n\n00:42.187 --> 00:46.487\n一是糖哮哮喘治疗药物，\n\n00:46.838 --> 00:49.388\n包括吸入性的皮质激素。\n\n00:51.645 --> 00:52.346\n类固醇。\n\n00:53.477 --> 00:55.126\n长效的白色受体激动剂，\n\n00:55.126 --> 00:56.926\n用于控制症状和预防发作。\n\n00:58.066 --> 01:00.015\n治疗效果的局限性。\n\n01:00.515 --> 01:03.465\n尽管现有的药物能有效的控制哮喘，\n\n01:03.916 --> 01:07.066\n但仍有部分患者对治疗反应是不佳的。\n\n01:08.387 --> 01:09.787\n症状难以完全控制。\n\n01:11.003 --> 01:12.253\n治疗依从性问题，\n\n01:12.503 --> 01:16.903\n患者对治疗方案的依从性是导致哮喘的控制率不高的一个。\n\n01:17.652 --> 01:18.302\n重要因素，\n\n01:18.351 --> 01:20.851\n需要提高患者的教育和管理。\n\n01:23.588 --> 01:24.814\n新型的治疗策略，\n\n01:24.814 --> 01:28.613\n生物制剂和精准治疗的出现，\n\n01:28.613 --> 01:31.939\n为难治性哮喘患者提供了新的治疗选择。\n\n01:32.658 --> 01:33.958\n改善了治疗的效果。\n\n01:40.869 --> 01:42.268\n新药研发的需求。\n\n01:44.518 --> 01:46.069\n现有的药物局限性。\n\n01:46.981 --> 01:48.930\n当前的哮喘治疗药物虽多，\n\n01:49.280 --> 01:51.905\n但存在不能当长期使用，\n\n01:51.905 --> 01:53.430\n效果递减的问题。\n\n01:54.225 --> 01:55.225\n迫切需要新药。\n\n01:56.336 --> 01:57.387\n患者个体差异，\n\n01:57.486 --> 01:59.787\n哮喘患者对药物反应差异大，\n\n02:00.186 --> 02:04.686\n需要研发能够针对不同患者的体质和病情的个体化。\n\n02:05.870 --> 02:06.269\n治疗。\n\n02:07.230 --> 02:09.130\n要提高生活质量。\n\n02:09.904 --> 02:13.304\n新药研发需关注监测患者日常的管理负担。\n\n02:14.399 --> 02:15.498\n追踪其生活资料。\n\n02:16.429 --> 02:17.580\n减少吸入频率，\n\n02:17.580 --> 02:18.830\n简化治疗步骤。\n\n02:24.597 --> 02:25.697\n研发团队的构成。\n\n02:27.397 --> 02:30.197\n一是跨学科的合作模式。\n\n02:31.033 --> 02:36.184\n研发团队通常包括乐理学家、临床医生和生物统计学家，\n\n02:36.583 --> 02:39.434\n以确保药物研发的科学性和实用性。\n\n02:40.296 --> 02:41.595\n临床试验专家。\n\n02:42.046 --> 02:45.445\n临床试验专家负责设计和执行临床试验，\n\n02:45.746 --> 02:48.546\n确保实验的安全性和有效性，\n\n02:48.996 --> 02:51.695\n以获得药物上市的必要数据。\n\n02:52.852 --> 02:58.102\n法规事务专家法规事务专家确保药物的研发过程不可。\n\n02:59.285 --> 03:05.434\n各国药品监管机构的规则为药物上市铺平那个道路？\n\n03:11.863 --> 03:13.014\n药的作用机制。\n\n03:15.481 --> 03:17.332\n这一项也是很好的内容。\n\n03:18.539 --> 03:18.889\n宝宝。\n\n03:19.805 --> 03:21.106\n药物的成分分析。\n\n03:22.820 --> 03:24.345\n还有左右原理的算术。\n\n03:26.013 --> 03:27.013\n用药的成分分析，\n\n03:27.063 --> 03:28.912\n包括贝塔受体激动剂。\n\n03:29.815 --> 03:32.766\n这类药物通过激活白塔肾上腺素受体。\n\n03:33.686 --> 03:36.335\n黄酮气道平滑肌缓解哮喘症状。\n\n03:37.233 --> 03:38.033\n皮质类固醇。\n\n03:39.259 --> 03:39.910\n配色类固醇，\n\n03:39.910 --> 03:41.960\n减少气道炎症，\n\n03:42.059 --> 03:44.509\n降低气道对过敏原的敏感性，\n\n03:44.509 --> 03:47.360\n是长期控制哮喘的关键成分。\n\n03:48.942 --> 03:50.341\n抗白三烯的药物，\n\n03:50.341 --> 03:52.992\n抗白三烯药物阻断白三烯的作用。\n\n03:53.723 --> 03:55.649\n减少气道炎症和痉挛。\n\n03:55.649 --> 03:57.673\n用于治疗中、重症的哮喘。\n\n03:59.796 --> 04:00.371\n原理，\n\n04:00.371 --> 04:00.847\n算术。\n\n04:02.166 --> 04:05.565\n一是药物与受体的相互作用。\n\n04:05.966 --> 04:09.966\n新型药物通过与气道平滑肌上白塔受体结合。\n\n04:10.871 --> 04:12.397\n激活腺苷黄化酶，\n\n04:12.397 --> 04:14.472\n增加细胞内的环MP。\n\n04:15.283 --> 04:16.384\n从而放松气道。\n\n04:17.472 --> 04:19.947\n这些炎症信号通路的调节用，\n\n04:19.947 --> 04:23.472\n能够抑制炎症细胞的活化和炎症介质的释放，\n\n04:23.822 --> 04:25.122\n减少气道炎症，\n\n04:25.122 --> 04:26.673\n改善哮喘的症状。\n\n04:27.635 --> 04:28.635\n免疫调节功能，\n\n04:28.835 --> 04:34.485\n某些新型的药物通过调节免疫系统减少过敏反应。\n\n04:35.162 --> 04:36.988\n降低气道高反应性，\n\n04:36.988 --> 04:38.963\n增强哮喘患者的免疫耐受。\n\n04:42.019 --> 04:43.118\n疗效对比研究。\n\n04:44.933 --> 04:48.708\n一是新型药物与传统药物的疗效比较。\n\n04:49.722 --> 04:55.122\n新型药物在临床试验中展示出比传统药物更显著的疗效，\n\n04:55.122 --> 04:56.972\n有效控制哮喘的症状。\n\n04:57.924 --> 05:00.924\n长期使用新型药物的疗效稳定性。\n\n05:01.770 --> 05:03.145\n长期跟踪研究显示，\n\n05:03.145 --> 05:05.121\n新型药物在持续使用后。\n\n05:05.885 --> 05:08.785\n哮喘的控制率和生活质量有显著的提升。\n\n05:10.033 --> 05:16.783\n副作用发生率的对比分析新型药物在减少副作用方面表现出的优势，\n\n05:17.234 --> 05:18.484\n与传统药物相比，\n\n05:18.484 --> 05:20.183\n副作用发生率是更低的。\n\n05:26.369 --> 05:27.619\n这个零三。\n\n05:28.915 --> 05:30.015\n临床试验的结果。\n\n05:32.178 --> 05:33.678\n实验设计的概述。\n\n05:35.341 --> 05:37.091\n随机对照的实验。\n\n05:37.091 --> 05:41.341\n随机对照实验是评估新药炎效果的一个金标准。\n\n05:42.278 --> 05:43.204\n通过随机分配，\n\n05:43.204 --> 05:45.528\n确保实验组和最早组的可比性。\n\n05:46.885 --> 05:48.036\n剂量递增的研究。\n\n05:48.286 --> 05:51.936\n剂量递增研究用于确定药物的安全。\n\n05:52.846 --> 05:53.545\n剂量范围，\n\n05:54.045 --> 05:57.795\n通过逐步增加剂量来评估药物的安全性和耐受性。\n\n05:58.705 --> 05:59.406\n双盲设计，\n\n05:59.406 --> 06:00.480\n在双盲设计中，\n\n06:00.480 --> 06:03.406\n研究者和参与者均不做水解，\n\n06:03.406 --> 06:04.705\n受了新药和安慰剂，\n\n06:04.705 --> 06:06.705\n以减少偏见和主观影响。\n\n06:07.791 --> 06:12.592\n长期随访研究长期随访研究关注药物长期使用的安全性和有效性。\n\n06:13.506 --> 06:17.355\n通过跟踪患者的状况来收集数据。\n\n06:20.329 --> 06:21.678\n数据手机号分析。\n\n06:24.773 --> 06:27.222\n这个患者的症状改善的评估，\n\n06:27.423 --> 06:29.122\n通过问卷调查。\n\n06:29.997 --> 06:30.847\n和日常的。\n\n06:31.834 --> 06:32.834\n检测记录。\n\n06:34.095 --> 06:38.095\n手机患者使用新药后的症状变化数据与评估疗效。\n\n06:39.187 --> 06:40.537\n肺功能的测试结果，\n\n06:40.588 --> 06:43.388\n定期进行肺功能测试与ICU。\n\n06:44.593 --> 06:44.944\n测量，\n\n06:45.044 --> 06:47.944\n以客观数据反映药物对肺功能的影响。\n\n06:49.700 --> 06:52.126\nFUY就是第一秒用这个呼吸溶剂。\n\n06:54.882 --> 06:55.782\n不良反应记录。\n\n06:55.833 --> 07:00.583\n详细记录患者在临床试验期间出现的任何不良反应，\n\n07:00.583 --> 07:02.433\n分析新药的安全性。\n\n07:03.429 --> 07:04.630\n长期的跟踪数据，\n\n07:04.679 --> 07:07.579\n对患者进行长期的跟踪，\n\n07:07.929 --> 07:11.079\n确保关于药物的长期疗效和安全性的数据。\n\n07:11.981 --> 07:14.032\n以支持临床的决策。\n\n07:17.040 --> 07:18.290\n实验结果的总结。\n\n07:19.221 --> 07:21.221\n药物的疗效显著上升。\n\n07:25.282 --> 07:30.782\n新型的药物在临床试验中其实对哮喘症状的显著改善，\n\n07:30.833 --> 07:33.032\n有效降低了发作频率。\n\n07:34.279 --> 07:36.130\n再就是副作用发生率。\n\n07:36.380 --> 07:37.779\n对的药物。\n\n07:39.410 --> 07:39.785\n相比，\n\n07:39.785 --> 07:41.959\n新型药物的副作用发生率较低，\n\n07:42.359 --> 07:43.910\n患者耐受性良好。\n\n07:45.138 --> 07:46.287\n长期控制，\n\n07:46.287 --> 07:47.138\n效果稳定。\n\n07:47.954 --> 07:49.154\n实验数据表明。\n\n07:49.989 --> 07:54.489\n新型的药物在长期使用中能够持续稳定的控制哮喘症状。\n\n07:55.428 --> 07:58.578\n减少急性发作患者生活质量的改善。\n\n07:59.522 --> 08:02.821\n参与实验的哮喘患者报告称，\n\n08:03.171 --> 08:04.471\n使用新型药物后，\n\n08:04.471 --> 08:07.321\n我们的日常活动受限状况有所减少，\n\n08:07.622 --> 08:09.372\n生活质量得到提升。\n\n08:13.872 --> 08:15.671\n零四药物推广与应用。\n\n08:17.330 --> 08:18.930\n医疗机构的合作。\n\n08:21.350 --> 08:23.825\n一个是建立专业培训项目。\n\n08:24.940 --> 08:28.040\n合作医院开展针对哮喘治疗的医护人员培训。\n\n08:28.756 --> 08:30.855\n提升药物使用和管理的专业性。\n\n08:31.785 --> 08:33.734\n第二是共同开展临床实验。\n\n08:34.625 --> 08:39.474\n医疗机构、药物研发机构合作进行新药的临床试验。\n\n08:40.237 --> 08:42.187\n确保药物的安全性和有效性。\n\n08:43.500 --> 08:44.901\n推广健康教育活动。\n\n08:45.000 --> 08:46.651\n通过医疗机构举办。\n\n08:47.744 --> 08:49.195\n哮喘健康教育活动，\n\n08:49.294 --> 08:52.294\n提高公众对新型药物的认知和接受度。\n\n08:54.492 --> 08:55.442\n换的交易计划。\n\n08:56.627 --> 08:58.778\n就是哮喘管理知识普及。\n\n08:59.565 --> 09:01.414\n通过举办讲座和发放资料，\n\n09:01.414 --> 09:02.765\n教育患者正确。\n\n09:03.851 --> 09:06.950\n如何正确使用新型药物以及日常活动中的。\n\n09:08.343 --> 09:10.343\n管理哮喘药物使用演示，\n\n09:10.543 --> 09:12.942\n演示新型药物的正确使用方法。\n\n09:13.752 --> 09:15.552\n保证吸入器的使用技巧，\n\n09:15.651 --> 09:18.601\n确保患者的能够熟练掌握，\n\n09:19.252 --> 09:21.052\n做过检测与急救培训。\n\n09:21.968 --> 09:24.294\n教授患者如检测症状，\n\n09:24.294 --> 09:25.718\n使用急救药物，\n\n09:26.018 --> 09:28.818\n提高他们应对哮喘发作的能力。\n\n09:32.044 --> 09:34.893\n市场反馈的手机患者满意度调查，\n\n09:35.393 --> 09:39.994\n通过问卷或访谈手机患者使用新型哮喘药物的满意度。\n\n09:40.752 --> 09:43.302\n以评估药物的实际效果和改善空间。\n\n09:44.187 --> 09:45.338\n医生反馈汇总，\n\n09:45.338 --> 09:47.338\n定期与医生沟通，\n\n09:47.788 --> 09:52.388\n收集他们对新型药物的疗效、副作用和使用便捷性的专业反馈。\n\n09:53.385 --> 09:54.534\n消除数据分析。\n\n09:54.585 --> 09:56.385\n分析药物消除数据，\n\n09:56.734 --> 10:00.585\n了解市场的接受度和潜在的营销趋势，\n\n10:00.984 --> 10:03.484\n为市场策略调整提供依据。\n\n10:08.421 --> 10:10.072\n05是未来研究的方向。\n\n10:12.213 --> 10:13.663\n业务的改进计划。\n\n10:15.033 --> 10:16.757\n开发长效控制药物。\n\n10:16.757 --> 10:20.708\n研究者正致力于开发新的长效哮喘控制药物，\n\n10:21.057 --> 10:23.182\n以减少患者每日的服药次数，\n\n10:23.182 --> 10:24.357\n提高生活质量。\n\n10:25.364 --> 10:26.614\n增强药物的靶向性。\n\n10:26.664 --> 10:28.614\n通过改进药物的分子结构，\n\n10:28.965 --> 10:31.864\n增强其内气道炎症细胞的靶向性，\n\n10:32.164 --> 10:34.864\n以期达到精准的治疗效果，\n\n10:35.215 --> 10:36.364\n减少副作用。\n\n10:36.664 --> 10:39.715\n研发贯彻中注意药物的安全性，\n\n10:39.864 --> 10:42.914\n力求减少现有药物可引起的副作用。\n\n10:43.453 --> 10:45.203\n如激素类药物的副作用。\n\n10:46.263 --> 10:48.213\n再就是个性化药物的治疗，\n\n10:48.314 --> 10:54.213\n运用基因组学和生物标志物为患者提供个性化的药物治疗方案。\n\n10:54.888 --> 10:57.237\n以提高治疗的针对性和有效性。\n\n11:01.236 --> 11:04.036\n新研究探索针对不同。\n\n11:05.591 --> 11:07.091\n形成的药物的优化。\n\n11:07.291 --> 11:12.841\n研究团队正在探索药物对儿童和青少年哮喘患者适应性，\n\n11:13.190 --> 11:14.890\n以提高治疗的效果。\n\n11:15.711 --> 11:16.562\n又在运动。\n\n11:16.562 --> 11:17.062\n哮喘。\n\n11:18.179 --> 11:19.479\n运动诱发哮喘的应用，\n\n11:19.530 --> 11:26.429\n研究者关注药物在预防和控制运动哮喘中的潜力。\n\n11:27.705 --> 11:30.606\n以帮助运动员更好的管理症状。\n\n11:31.255 --> 11:34.656\n药物对慢性阻塞性肺疾病的疗效。\n\n11:35.465 --> 11:39.965\n科学家正在评估这些新型的药物是否能有效的治疗吸入PD。\n\n11:40.838 --> 11:42.138\n为患者提供新的。\n\n11:43.080 --> 11:43.931\n治疗选择。\n\n11:47.440 --> 11:49.190\n长期安全性要研究。\n\n11:50.929 --> 11:51.879\n进行的。\n\n11:53.005 --> 11:56.406\n哮喘药的长期使用可能带来副作用。\n\n11:57.213 --> 11:58.763\n确保药物的安全，\n\n11:59.013 --> 12:01.013\n就是药物的副作用检测。\n\n12:02.090 --> 12:06.140\n再就是评估新型药物与其他药物共用时的安全性。\n\n12:06.940 --> 12:09.239\n预防潜在的不良药物相互作用。\n\n12:09.239 --> 12:10.640\n药物相互作用评估。\n\n12:11.440 --> 12:15.690\n通过长期跟踪研究观察药物对哮喘控制的。\n\n12:16.653 --> 12:16.854\n嗯，\n\n12:16.854 --> 12:19.903\n实际效果以及可能的耐药性问题，\n\n12:19.903 --> 12:21.703\n长期的疗效跟踪。\n\n12:24.815 --> 12:25.166\n零六。\n\n12:26.291 --> 12:27.491\n社会影响评估。\n\n12:29.607 --> 12:31.507\n提升患者的生活质量。\n\n12:32.840 --> 12:35.340\n一是减少急性发作的次数。\n\n12:35.489 --> 12:39.390\n新型药物能有效的减少哮喘的急性发作，\n\n12:39.739 --> 12:40.914\n降低住院率，\n\n12:40.914 --> 12:43.940\n提高生活日常生活自由度。\n\n12:47.734 --> 12:48.133\n改善。\n\n12:49.866 --> 12:50.866\n睡眠质量。\n\n12:52.124 --> 12:53.773\n通过控制哮喘的症状，\n\n12:54.273 --> 12:58.573\n患者夜间咳嗽和呼吸困难的情况得到缓解，\n\n12:59.023 --> 13:00.773\n从而改善睡眠质量。\n\n13:01.875 --> 13:03.174\n增强运动耐力，\n\n13:03.174 --> 13:04.525\n有效的控制哮喘。\n\n13:04.525 --> 13:06.174\n后患者在运动时的。\n\n13:07.036 --> 13:08.562\n呼吸受限状况得到改善，\n\n13:08.562 --> 13:10.736\n能够参与更多的体力活动。\n\n13:13.616 --> 13:14.866\n医疗资源的优化。\n\n13:15.924 --> 13:17.424\n提高医疗服务质量。\n\n13:17.424 --> 13:19.325\n新型药物的引入，\n\n13:19.325 --> 13:21.724\n提升了哮喘的治疗效果，\n\n13:21.724 --> 13:23.375\n减少了患者的复发率，\n\n13:23.775 --> 13:26.174\n提高了整体的医疗服务水平。\n\n13:27.502 --> 13:28.851\n增强患者的依从性，\n\n13:29.052 --> 13:34.226\n新型药物的便利和有效性提高了患者用药依从性。\n\n13:34.226 --> 13:35.401\n有助于长期的。\n\n13:36.559 --> 13:37.659\n管理哮喘的症状，\n\n13:38.109 --> 13:39.460\n降低医疗成本。\n\n13:40.283 --> 13:41.434\n通过控制哮喘，\n\n13:41.633 --> 13:44.133\n减少急诊和住院次数，\n\n13:44.484 --> 13:47.333\n从而降低了医疗系统的经济负担。\n\n13:49.883 --> 13:52.434\n再就是公共卫生的贡献。\n\n13:53.724 --> 13:55.349\n这一项也是很重要的，\n\n13:55.349 --> 13:59.474\n新型药物的应用显著减少了哮喘患者的急诊次数。\n\n14:00.390 --> 14:01.565\n减轻了医疗的负担，\n\n14:01.565 --> 14:03.890\n降低哮喘相关的急诊率。\n\n14:05.044 --> 14:08.645\n新兴药物的普及减少了哮喘相关的长期医疗成本。\n\n14:09.044 --> 14:09.895\n优化了。\n\n14:10.828 --> 14:12.177\n公共卫生资源分配，\n\n14:12.278 --> 14:14.778\n减少医疗资源的消耗。\n\n14:16.101 --> 14:17.401\n提高患者生活质量，\n\n14:17.802 --> 14:19.802\n通过有效的控制哮喘的症状，\n\n14:19.802 --> 14:22.976\n新型药物帮助患者改善生活质量，\n\n14:22.976 --> 14:24.202\n减少活动受限。\n\n14:28.393 --> 14:33.293\n对于这个新药的研发内容还是蛮丰富蛮多的。\n\n14:34.031 --> 14:34.682\n大家都知道，\n\n14:34.682 --> 14:37.632\n哮喘目前的控制率还存在很多不足。\n\n14:38.484 --> 14:38.760\n继续。\n\n14:38.760 --> 14:39.184\n我们。\n\n14:41.372 --> 14:45.973\n医生和药物研发机构共同的合作。\n\n14:47.190 --> 14:48.616\n研发出新的药物来。\n\n14:49.567 --> 14:52.916\n从共同的来对抗我们哮喘的控制，\n\n14:53.267 --> 14:55.617\n这在临床上是极其重要的。\n\n14:57.502 --> 14:57.976\n当然，\n\n14:57.976 --> 15:01.151\n这也是一个漫长而精细的过程。\n\n15:02.177 --> 15:05.328\n无论是医生还是研发机构。\n\n15:06.265 --> 15:12.765\n都要拿出大量的精力、物力和财力来共同完成这项艰巨的任务，\n\n15:12.815 --> 15:14.664\n给哮喘患者带来福音。\n\n15:17.198 --> 15:17.448\n好，\n\n15:17.499 --> 15:21.249\n我这个课件的讲述就到这儿。\n\n15:22.122 --> 15:22.672\n谢谢大家。\n\n","v0347cg10004d76dacaljht2o53utqe0",923,774,"2026-01-24 23:37:04","新型药物显著提升哮喘控制率 - 最新治疗进展与效果分析  ","哮喘控制率,新型哮喘药物,哮喘治疗进展,哮喘管理,呼吸系统疾病  ","探索新型药物如何显著提升哮喘控制率，了解其作用机制、临床效果及患者受益情况。为您提供最新的哮喘治疗进展与科学管理方案。","2026-04-07 07:00:00",[38],{"menuId":39,"menuName":40,"parentId":17,"orderNum":41,"path":42,"component":43,"isFrame":44,"isCache":45,"menuType":46,"visible":27,"status":17,"createDept":6,"remark":25,"createTime":47,"children":48,"columnImage":49,"columnLogo":50,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":51,"seoKeywords":52,"seoDescription":53,"contentNum":6,"promotionalPoster":54,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":55,"routerPath":42,"componentInfo":43},"1986622624134549505","科普视频",3,"video","/video.html","1","0","T","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video",2,"慢性病",4,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/869990/9fc81f4f-4a67-42a4-8ada-7a87484e4b63.tmp?a=0&auth_key=1789024559-d2f42708f7b14711aeb44886a27c0661-0-58ccd6da68860a97105a6cf3d162d578&br=383&bt=383&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=3&eid=v0347cg10004d76dacaljht2o53utqe0&er=0&l=2026081105003347EF8E6E0E771E87A0FE&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=M3R4ODVrb2ZnOjczNGY3M0ApaHc2cndtZGQ5ZzMzajo2eWdicTBscWdeXjNhLS1kNDBzcy1ucjIvZWlgYTQxLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":59,"message":6,"data":6,"success":60},{"code":9,"msg":10,"message":6,"data":63,"success":60},{"pageNo":27,"pageSize":23,"result":64,"totalSize":17},[],{"code":9,"msg":10,"message":6,"data":66,"success":60},{"authors":67,"appraiseDimensionScoresVos":68},[],[]]